Literature DB >> 25549189

Postoperative stereotactic radiosurgery to the resection cavity for large brain metastases: clinical outcomes, predictors of intracranial failure, and implications for optimal patient selection.

Diane C Ling1, John A Vargo, Rodney E Wegner, John C Flickinger, Steven A Burton, Johnathan Engh, Nduka Amankulor, Annette E Quinn, Cihat Ozhasoglu, Dwight E Heron.   

Abstract

BACKGROUND: Postoperative stereotactic radiosurgery for brain metastases potentially offers similar local control rates and fewer long-term neurocognitive sequelae compared to whole brain radiation therapy, although patients remain at risk for distant brain failure (DBF).
OBJECTIVE: To describe clinical outcomes of adjuvant stereotactic radiosurgery for large brain metastases and identify predictors of intracranial failure and their implications on optimal patient selection criteria.
METHODS: We performed a retrospective review on 100 large (>3 cm) brain metastases in 99 patients managed by resection followed by postoperative stereotactic radiosurgery to a median dose of 22 Gy (range, 10-28) in 1 to 5 fractions (median, 3). Primary histology was nonsmall cell lung in 40%, breast cancer in 18%, and melanoma in 17%. Forty (40%) patients had uncontrolled systemic disease.
RESULTS: With a median follow-up of 12.2 months (range, 0.6-87.4), the 1-year Kaplan-Meier local control was 72%, DBF 64%, and overall survival 55%. Nine patients (9%) developed evidence of radiation injury, and 6 (6%) developed leptomeningeal disease. Uncontrolled systemic disease (P=.03), melanoma histology (P=.04), and increasing number of brain metastases (P<.001) were significant predictors of DBF on Cox multivariate analysis. Patients with <4 metastases, controlled systemic disease, and nonmelanoma primary (n=47) had a 1-year DBF of 48.6% vs 80.1% for all others (P=.01).
CONCLUSION: Postoperative stereotactic radiosurgery to the resection cavity safely and effectively augments local control of large brain metastases. Patients with <4 metastases and controlled systemic disease have significantly lower rates of DBF and are ideal treatment candidates.

Entities:  

Mesh:

Year:  2015        PMID: 25549189     DOI: 10.1227/NEU.0000000000000584

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  16 in total

1.  Point/Counterpoint: Is stereotactic radiosurgery needed following resection of brain metastasis?

Authors:  Riccardo Soffietti; Roberta Rudà; Nicholas Trakul; Eric L Chang
Journal:  Neuro Oncol       Date:  2016-01       Impact factor: 12.300

2.  Post-operative management of brain metastases: GRADE-based clinical practice recommendations on behalf of the Italian Association of Radiotherapy and Clinical Oncology (AIRO).

Authors:  Chiara Reverberi; Stefania Volpe; Stefano M Magrini; Stefano Arcangeli; Damiano Balestrini; Michela Buglione; Piera Navarria; Silvia Scoccianti; Pierpaolo Panciani; Marco Krengli; Luigi Pirtoli; Lorenzo Bordi; Giovanni L Pappagallo; Rolando M D ' Angelillo
Journal:  J Cancer Res Clin Oncol       Date:  2021-01-23       Impact factor: 4.553

3.  Treatment of brain oligometastases with hypofractionated stereotactic radiotherapy utilising volumetric modulated arc therapy.

Authors:  Jeremy Croker; Benjamin Chua; Anne Bernard; Maryse Allon; Matthew Foote
Journal:  Clin Exp Metastasis       Date:  2015-10-19       Impact factor: 5.150

4.  HFSRT of the resection cavity in patients with brain metastases.

Authors:  Hanno M Specht; Kerstin A Kessel; Markus Oechsner; Bernhard Meyer; Claus Zimmer; Stephanie E Combs
Journal:  Strahlenther Onkol       Date:  2016-03-10       Impact factor: 3.621

5.  The radiosurgery fractionation quandary: single fraction or hypofractionation?

Authors:  John P Kirkpatrick; Scott G Soltys; Simon S Lo; Kathryn Beal; Dennis C Shrieve; Paul D Brown
Journal:  Neuro Oncol       Date:  2017-04-01       Impact factor: 12.300

6.  Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO).

Authors:  Riccardo Soffietti; Ufuk Abacioglu; Brigitta Baumert; Stephanie E Combs; Sara Kinhult; Johan M Kros; Christine Marosi; Philippe Metellus; Alexander Radbruch; Salvador S Villa Freixa; Michael Brada; Carmine M Carapella; Matthias Preusser; Emilie Le Rhun; Roberta Rudà; Joerg C Tonn; Damien C Weber; Michael Weller
Journal:  Neuro Oncol       Date:  2017-02-01       Impact factor: 12.300

7.  Postoperative radiosurgery for the treatment of metastatic brain tumor: Evaluation of local failure and leptomeningeal disease.

Authors:  Paul M Foreman; Bradford E Jackson; Karan P Singh; Andrew K Romeo; Barton L Guthrie; Winfield S Fisher; Kristen O Riley; James M Markert; Christopher D Willey; Markus Bredel; John B Fiveash
Journal:  J Clin Neurosci       Date:  2017-12-14       Impact factor: 1.961

8.  Resection Followed by Involved-Field Fractionated Radiotherapy in the Management of Single Brain Metastasis.

Authors:  Samuel M Shin; Ralph E Vatner; Moses Tam; John G Golfinos; Ashwatha Narayana; Douglas Kondziolka; Joshua Seth Silverman
Journal:  Front Oncol       Date:  2015-09-22       Impact factor: 6.244

9.  Intracranial control after Cyberknife radiosurgery to the resection bed for large brain metastases.

Authors:  Jennifer Vogel; Eric Ojerholm; Andrew Hollander; Cynthia Briola; Rob Mooij; Michael Bieda; James Kolker; Suneel Nagda; Geoffrey Geiger; Jay Dorsey; Robert Lustig; Donald M O'Rourke; Steven Brem; John Lee; Michelle Alonso-Basanta
Journal:  Radiat Oncol       Date:  2015-10-31       Impact factor: 3.481

10.  Outcome Evaluation of Oligometastatic Patients Treated with Surgical Resection Followed by Hypofractionated Stereotactic Radiosurgery (HSRS) on the Tumor Bed, for Single, Large Brain Metastases.

Authors:  Federico Pessina; Pierina Navarria; Luca Cozzi; Anna Maria Ascolese; Giulia Maggi; Marco Riva; Giovanna Masci; Giuseppe D'Agostino; Giovanna Finocchiaro; Armando Santoro; Lorenzo Bello; Marta Scorsetti
Journal:  PLoS One       Date:  2016-06-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.